Praxis outlines launch plans for two drug candidates
We haven't written up this one. Investing.com has the full story — the link below goes straight to it.
More in Finance & Markets
Cerebras reports Q3 core revenue up 70% YoY to $230.9M, vs. $214.7M est., issues strong guidance, and announces a Microsoft deal; CBRS jumps 15%+ after hours (Jordan Novet/CNBC)
Cerebras Systems reported better-than-expected revenue and quarterly guidance in its earnings report on Thursday, and touted a new deal with Microsoft.
CAVA vs. Hershey: Which Stock Is a Better Buy for 2027?
Key PointsCAVA continues to expand its footprint as a dominant leader in the Mediterranean fast-casual category.
Oil Supertanker Squeeze Is Crimping US Crude Exports, Texas Port CEO Says
A shortage of available oil supertankers is constraining US crude exports, prompting shippers to hire smaller vessels and direct more cargoes to Europe, according to the head of the largest US port.
SuperCom (SPCB) Q3 2026 Earnings Call Transcript
Foreign exchange losses and slower European ordering shaped the quarter.
Ideal Power (IPWR) Q3 2026 Earnings Call Transcript
Cash burn stayed in guidance while B-TRAN targets AI data centers and EVs.